Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5868698 | 0.95 | KDM1A (0.44) | KDM1AMAOBMAOAGNAI3GNAO1 | |
| SCHEMBL1009313 | 0.90 | GNAI3 (0.44) | KDM1AMAOBMAOAGNAI3GNAO1 | |
| SCHEMBL13838034 | 0.89 | RAD52 (0.47) | KDM1AMAOBMAOAGNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL4796821 | 0.88 | GNAI3 (0.47) | KDM1AMAOBMAOAGNAI3GNAO1 | |
| SCHEMBL27911707 | 0.87 | KDM1A (0.44) | KDM1AMAOBMAOAGNAI3GNAO1 | |
| SCHEMBL4264468 | 0.86 | KDM1A (0.47) | KDM1AMAOBMAOAGNAI3GNAO1 | |
| SCHEMBL4258478 | 0.86 | KDM1A (0.47) | KDM1AMAOBMAOAGNAI3GNAO1 | |
| SCHEMBL3307772 | 0.86 | GNAI3 (0.41) | KDM1AMAOBMAOAGNAI3GNAO1 | |
| SCHEMBL4261850 | 0.86 | KDM1A (0.47) | KDM1AMAOBMAOAGNAI3GNAO1 | |
| SCHEMBL27804953 | 0.86 | GNAI3 (0.41) | KDM1AMAOBMAOAGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103857393-A | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE LLC | 2014-06-11 | — | — | CN | claimed |
| US-12281116-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4433471-A1 | N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | CHDI Foundation, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118510769-A | HTT modulators for the treatment of huntington's disease | CHDI基金会股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023091456-A1 | N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091456-A1 | N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| EP-2688568-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| WO-2017158136-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS, S.A. (ES) | 2017-09-21 | — | — | WO | disclosed |
| CN-107001318-A | N- (hetero) aryl-substituted heterocyclic derivatives useful for the treatment of diseases or disorders associated with the central nervous system | 克罗诺斯治疗有限公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-103857393-A | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE LLC | 2014-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281116-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | KDM1A 3172/4885MAOB 1600/4885MAOA 1737/4885 |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | KDM1A 3172/4885MAOB 1600/4885MAOA 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.